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Manganese-enhanced t1 
mapping to quantify myocardial 
viability: validation with 
18F-fluorodeoxyglucose positron 
emission tomography
nick Spath  1*, Adriana tavares1, Gillian A. Gray1, Andrew H. Baker1, Ross J. Lennen1,2, 
carlos J. Alcaide-corral2, Marc R. Dweck1,3, David e. newby1,3, phillip c. Yang4, 
Maurits A. Jansen1,2 & Scott i. Semple1
Gadolinium chelates are widely used in cardiovascular magnetic resonance imaging (MRi) as passive 
intravascular and extracellular space markers. Manganese, a biologically active paramagnetic 
calcium analogue, provides novel intracellular myocardial tissue characterisation. We previously 
showed manganese-enhanced MRI (MEMRI) more accurately quantifies myocardial infarction than 
gadolinium delayed-enhancement MRi (DeMRi). Here, we evaluated the potential of MeMRi to assess 
myocardial viability compared to gold-standard 18F-fluorodeoxyglucose (18f-fDG) positron emission 
tomography (pet) viability. coronary artery ligation surgery was performed in male Sprague-Dawley 
rats (n = 13) followed by dual MEMRI and 18F-FDG PET imaging at 10–12 weeks. MEMRI was achieved 
with unchelated (EVP1001-1) or chelated (mangafodipir) manganese. T1 mapping MRi was followed 
by 18f-fDG micro-pet, with tissue taken for histological correlation. MeMRi and pet demonstrated 
good agreement with histology but native t1 underestimated infarct size. Quantification of viability 
by MeMRi, pet and Mtc were similar, irrespective of manganese agent. MeMRi showed superior 
agreement with pet than native t1. MEMRI showed excellent agreement with PET and MTC viability. 
Myocardial MeMRi t1 correlated with 18F-FDG standard uptake values and influx constant but not 
native t1. Our findings indicate that MEMRI identifies and quantifies myocardial viability and has major 
potential for clinical application in myocardial disease and regenerative therapies.
Magnetic resonance imaging with gadolinium delayed-enhancement (DEMRI) has an increasingly important 
role in assessing myocardial viability by quantifying transmurality of scar1,2. With DEMRI, gadolinium partitions 
into the extracellular space including tissue with membrane disruption due to infarction and fibrosis. Although 
readily available clinically, DEMRI only describes infarcted or scarred tissue, from which viability is inferred. It 
cannot not directly assess viability, but does assess scar burden as a surrogate from which to predict the likelihood 
of functional recovery. Furthermore, long-term safety questions have recently been raised around some gadolin-
ium formulations3–5. These limitations highlight the increasing need for novel cardiac MRI contrast media.
Manganese is a paramagnetic calcium analogue which is biologically active. It combines T1 shortening 
properties with intracellular uptake specifically defining myocardium with functional calcium-handling6. 
An essential trace element, manganese is fundamental to normal neurological, endocrine and bone develop-
ment and function7. Applied to cardiac MRI, the combination of paramagnetism with uptake by functional 
calcium-channels offers highly attractive potential to selectively define regions of myocardium with functioning 
calcium-cycling. As well as defining viable tissue, there is scope to detect altered calcium-handling states observed 
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in cardiomyopathies8. This technique has potential to add important functional assessment to current imaging 
with gadolinium delayed-enhancement which principally defines structure of pathology.
Unlike gadolinium, which has no known role in mammalian biology and is highly toxic in its unbound form9, 
manganese is naturally occurring with metabolic pathways for excretion providing a more attractive safety pro-
file10. Manganese-based contrast media can be administered in chelated (e.g. mangafodipir, manganese dipyri-
doxyl diphosphate, Mn-DPDP), or non-chelated (e.g. EVP1001-1, manganese gluconate with calcium gluconate) 
formulations. Both formulations demonstrate robust safety profiles in clinical studies whilst retaining favoura-
ble imaging properties. Our previous preclinical work demonstrated both these agents can be used to achieve 
MEMRI T1 mapping, which quantifies infarct size more accurately than DEMRI and DEMRI T1 mapping, and has 
potential to track and quantify altered calcium-handling in remodelling myocardium11.
Glucose is the substrate for myocardial energy. The radio-labelled glucose analogue 18F-fluorodeoxyglucose 
(18F-FDG) is used routinely in nuclear imaging to track metabolism-dependent processes. Applied to cardiac 
imaging, 18F-FDG positron emission tomography (PET) is the gold standard for assessing myocardial viabil-
ity12,13, offering the greatest sensitivity for viable myocardium and comparable specificity to other modalities1. 
Although18F-FDG PET necessitates exposure to radiation and its use is often limited by availability and expertise, 
imaging in this way directly assesses viability through metabolic functionality of tissues; a mechanistically sim-
ilar method of myocardial viability assessment to MEMRI. Comparison of MEMRI with the gold-standard of 
18F-FDG PET for myocardial viability assessment may therefore be of greater value than direct comparison with 
DEMRI techniques.
We aimed to compare and validate the quantification of viable myocardium by MEMRI T1 mapping using two 
distinct clinical grade agents and 18F-FDG PET in a rodent model of myocardial infarction. This novel compari-
son of MEMRI with 18F-FDG PET builds on previous preclinical work and is an essential mechanistic precursor 
to enable clinical translation of this contrast agent with notable potential for true viability assessment in cardiac 
MRI.
Methods
All experiments were approved by the University of Edinburgh Animal Welfare and Ethical Review Body 
(713-LF2-16), carried out according to UK Home Office Animals (Scientific Procedures) Act 1986 (Project 
Licence 70/8933) and the European Parliament Directive on the protection of animals used for scientific purposes 
(2010/63/EU). Male Sprague Dawley rats (180–300 g, n = 16, Charles River Ltd, Haddington, UK) with free access 
to food and water and no dietary restrictions, were housed in the Bioresearch facilities, University of Edinburgh 
and allowed to acclimatise for 7 days prior to use in the study.
Myocardial infarction model. Inhaled agents were exclusively used for anaesthesia, to allow rapid recovery 
in an effort to reduce peri-operative mortality, as advised by institutional veterinarians. Rats were anaesthetised 
with isoflurane (5% in 1.5 L/min oxygen) and maintenance anaesthesia (2–3% in 1 L/min oxygen). For analgesia, 
buprenorphine 0.05 mg/kg (Alstoe Ltd, York, UK) was administered before surgery and as required for 24 hours 
post-operatively. Anaesthetic depth was monitored throughout and deemed adequate by the absence of neuro-
logical response to painful physical stimulus. Using a bespoke intubation rig, the trachea was intubated under 
direct vision whilst maintaining inhaled nasal anaesthesia, whereby ventilation was subsequently established and 
maintained with a rodent ventilator (Harvard Apparatus Model 683, MA, USA, tidal volume 2.5 cm3, respiratory 
rate 60/min). Myocardial infarction was induced as previously described11. In brief, lateral thoracotomy was per-
formed at the third or fourth intercostal space, the left lung collapsed and the pericardium ruptured. The heart 
was gently exteriorised and a non-absorbable 5-0 ligature placed around the left anterior descending coronary 
artery just above the bifurcation of the first diagonal, before being replaced in the thorax. Excess air and fluid were 
aspirated from the thorax as the wound was closed in three layers. Animals were weaned from inhaled anaesthesia 
over 5–10 minutes and extubated once spontaneous ventilation was re-established, housed at 30 °C for 24 hours 
and given sterile sodium chloride 0.9% 0.01 mL/g fluid therapy subcutaneously. After 24 hours, normal housing 
conditions were resumed.
Magnetic resonance image acquisition and reconstruction. MRI with T1 mapping was per-
formed using the methods previously described11. In brief, a 7 T horizontal bore NMR spectrometer (Agilent 
Technologies, Yarnton, UK), equipped with a high-performance gradient insert (120-mm inner diameter), max-
imum gradient strength 400 mT/m. Rats were anaesthetised using 1.5–2% isoflurane (Zoetis Ltd., London UK) 
in oxygen/air (50/50, 1 L/min), the tail vein cannulated and placed in a cradle (Rapid Biomedical GmbH, Rimpar, 
Germany). A 72-mm quadrature volume coil was used for transmission with signal reception by a four-channel 
phased array coil (Rapid Biomedical GmbH, Rimpar, Germany). Heart rate, respiration rate, and temperature 
were monitored (Model 1030 monitoring and gating system, Small Animal Instruments Inc., Stony Brook, NY, 
USA), maintained at 37 °C.
All imaging was performed 12 weeks after surgery (Fig. 1). This time point was chosen to assess established 
myocardial infarction with left ventricular remodelling, in line with our previous work in this field11. Cine imag-
ing was acquired in long and short-axis stack orientation (9 × 2 mm slices) from the aortic valve annulus to the 
apex, perpendicular to the interventricular septum, using cardiac-gated gradient echo imaging (TR = 6.35 ms; 
TE = 1.4 ms; flip angle = 15°; FOV = 50 × 50 mm2; matrix = 128 × 128; slice thickness = 1.5 mm). The final slice 
plan and orientation was agreed and documented by two adjudicators (NS/MAJ) at the time of image acquisition 
to optimise repeatability between scans. Similarly, a single short-axis slice at the maximal infarct region was then 
agreed and the precise slice location recorded.
Native T1 mapping was performed for calculation of regional myocardial T1 relaxation times using a 
gradient-echo, cardiac-gated Modified Look-Locker Inversion recovery sequence (MoLLI). Images (n = 14–20) 
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were acquired at inversion times determined by R-R interval, with the TRinversion > 3xT1 of myocardium 
(TRinversion > 4.50 s). Image readout was with a cardiac fast gradient echo (TR = 3.50 ms; TE = 1.77 ms; flip 
angle = 10°, matrix 128 × 128; Echo train length = 8; FOV = 50 × 50 mm2; in-plane resolution = 0.39 × 0.39 mm2; 
trigger delay = 1xR-R; slice thickness = 2 mm; 8 signal averages to compensate for respiratory motion).
MEMRI T1 mapping was achieved using either EVP1001-1 or mangafodipir (22 μmol/kg, n = 6 and 44 μmol/
kg, n = 7 respectively), administered via slow intravenous injection into the tail vein over 1–2 min. Optimal dose 
and timings for post-contrast imaging differ between these agents, as we have previously demonstrated11. Optimal 
myocardial T1 shortening is achieved by 20 min for EVP1001-1 and from 40 min after administration of mangafo-
dipir. T1 mapping was performed at the identical maximal infarct slice to native T1 mapping, as above.
18F-fDG pet/ct image acquisition and reconstruction. Maintained under inhaled anaesthesia, 
animals were transferred to a micro-PET/CT scanner (Nanoscan, Mediso Medical Imaging Systems, Hungary) 
whereby tail-prick blood glucose was measured prior to administration of intravenous 18F-FDG (20–30 MBq). 
PET data were acquired continually for 60 min immediately following intravenous radiotracer administration. A 
CT scan (semi-circular full trajectory, maximum field of view, 480 projections, 50 kVp, 300 ms and 1:4 binning) 
was acquired for attenuation correction. The emission dynamic 60-min scan was obtained using 3-dimensional 
1:5 mode and re-binned as follows: 6 × 1 min; 7 × 2 min; 8 × 5 min. PET images were reconstructed using Mediso’s 
iterative Tera-Tomo 3D reconstruction algorithm and the following settings: 4 iterations, 6 subsets, full detector 
model, low regularization, spike filter on, voxel size 0.4 mm and 400–600 keV energy window. PET data were 
corrected for random co-incidents, scatter and attenuation.
image analysis. MRI image analysis was performed with identical methodology to previously described, 
including normalisation of T1 maps to the skeletal muscle for direct comparison of T1 values11. This was necessary 
due to high variation in T1 values measured before and after contrast due mainly to beat-to-beat variation in heart 
rate during prolonged anaesthesia. Baseline skeletal muscle T1 values for pre- (T1bsm) and post-contrast (T1sm) T1 
maps were calculated from regions of interest (ROI) drawn in the chest wall in the intercostal muscles. The ratio 
of skeletal muscle T1 values (T1bsm/T1sm) was used to normalise the T1 maps at each time point using the equation 
nT1x,y = T1x,y x (T1bsm/T1sm) where T1x,y is the absolute T1 of voxels within the ROI and nT1x,y is the normalised T1 
of voxels within the ROI.
The 14–20 images at unique inversion times were exported offline and incorporated with individual heart 
rate and trigger delay data using Matlab (MathWorks Inc., USA). T1 maps were then generated and ana-
lysed with commercially available software (CVI4.2®, Circle Cardiovascular Imaging, Calgary, Canada) using 
three-parameter non-linear curve fitting as previously described and standardized colour scales. Endocardial and 
epicardial contours drawn on MoLLI images were copied to the T1 map, once generated. Infarcted myocardium 
was defined as ≥ 2 x standard deviations of remote myocardial T1. Consecutive short-axis MRI cine slices were 
reconstructed to form a single 3D dataset [ImageJ, v1.5114] for co-registration with PET data.
PET data were analysed in the commercially available software (PMOD version 3.8, Fusion module, PMOD 
Technologies Limited, Zurich Switzerland), whereby PET and MR images were co-registered and fused. Endo-/
epicardial contours were defined by MRI data with extent of PET uptake denoting myocardial viability. Presence 
of myocardium without PET uptake was defined as myocardial infarction, represented as a percentage short-axis 
slice corresponding to the T1 mapping slice. Rate of myocardial uptake 18F-FDG was then modelled using Patlak 
analysis15 to calculate influx constant (Ki) for remote myocardium (PMOD version 3.8, PMOD Technologies 
Limited, Zurich Switzerland).
Histopathology. Animals were euthanised by overdose of isoflurane until circulatory arrest, followed by 
exsanguination. Hearts were fixed using immersion-fixation in 4% paraformaldehyde for 24 hours before trans-
fer to 70% ethanol and processed to paraffin wax for sectioning. Serial 5-µm short-axis sections from apex to 
base were taken, registered to MRI short axis T1 map positions. Samples were stained with Masson’s trichrome 
(MTC) to delineate collagenous fibrosis, staining replacement scar tissue in the infarct blue and the non-infarcted 
myocardium purple, before mounting for computer-aided analysis. Slides were scanned at 20x magnification on 
a Zeiss Axioscan Z1 (Carl Zeiss AG, Oberkochen, Germany). Infarct size was calculated as a percentage of total 
left ventricular area at the corresponding maximal infarct slice as defined by MRI. Automated tissue detection 
was performed (Tissue Studio v2.4, Definiens AG, Munich, Germany) as previously described11 producing pixel 
counts and areas for the ROIs within the left ventricle, from which percentage infarct area at maximal infarct slice 
was calculated.
Figure 1. Experimental protocol. Flow chart of experimental protocol.
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Statistical analysis. Data are presented as mean ± standard deviation unless otherwise stated. Normality 
was assessed using the D’Agostino-Pearson test. For infarct quantification, native T1 mapping, MEMRI T1 map-
ping, PET non-viability and MTC assessments were compared using paired t-test and ANOVA (with Tukey’s 
multiple comparisons testing). Bland-Altman plots were used to assess agreement between native T1 mapping, 
MEMRI T1 mapping, PET non-viability and MTC. Spearman’s rank correlation tested for relationship between 
measures of 18F-FDG PET uptake (standardized uptake values [SUV] or influx constant [Ki], dependent var-
iables) and remote myocardial indexed T1 values (native or post-MEMRI, independent variables). Statistical 
analysis was performed using GraphPad PRISM (v.7.0, GraphPad Software Inc., La Jolla, CA, USA). Statistical 
significance was taken as two-sided P < 0.05.
ethics. Ethical approval was granted for all animal studies by the University of Edinburgh Animal Welfare 
and Ethical Review Body (713-LF2-16), in accordance with the Animals (Scientific Procedures) Act, UK, 1986.
Results
Surgical outcomes. No animals died unexpectedly after recovering from surgery. Twelve weeks follow-
ing surgery, all animals had left ventricular impairment with reduced ejection fraction (38.2 ± 10.2%). Whilst 
some variation in infarct size was seen, there were no differences between animals undergoing MEMRI with 
mangafodipir or EVP1001-1 in ejection fraction (39.2 ± 9.5% and 37.0 ± 10.8%, P = 0.69), end-diastolic volume 
(1.0 ± 0.2mls and 0.9 ± 0.2mls, P = 0.95) or left ventricular mass (0.7 ± 0.1 g and 0.7 ± 0.1 g, P = 0.40).
Myocardial viability. Quantification of viable myocardium was similar whether determined by PET, 
MEMRI T1 or MTC (Figs. 2 and 3), irrespective of manganese contrast agent (one-way ANOVA, Mangafodipir 
P = 0.12, EVP1001-1 P = 0.50). In contrast, viability quantification by native T1 mapping was lower than MEMRI 
T1 mapping (P < 0.01), PET (P < 0.01) or MTC (P = 0.03). Mangafodipir and EVP1001-1 independently demon-
strated good agreement (Bland-Altman) with both PET (bias 0.22%, 95% CIs of LoA −3.69 to 4.12, P = 0.78 and 
bias 0.05%, 95% CIs of LoA −7.13 to 7.22, P > 0.9 respectively) and MTC quantification of viable myocardium 
(bias −1.41%, 95% CIs of LoA −5.79 to 2.94, P = 0.15 and bias 0.1.09%, 95% CIs of LoA −2.27 to 4.44, P = 0.18 
respectively).
Bland-Altman analysis demonstrated excellent agreement of MEMRI T1 mapping and PET with MTC (bias 
−0.14%, 95% confidence intervals [CIs] of limits of agreement [LoA] −5.72 to 5.43, [P = 0.70] and bias −0.86%, 
95% CIs of LoA −6.89 to 5.17 [P = 0.58] respectively), and this was superior to that of native T1 mapping, which 
tended to underestimate the amount of viable myocardium (bias −3.91%, 95% CIs of LoA −12.24-4.43, P = 0.006; 
Fig. 4). When compared to PET, MEMRI T1 mapping demonstrated superior agreement over native T1 mapping, 
which again underestimated viable myocardium (bias −0.25%, 95% CIs of LoA −7.23 to 6.74, P = 0.86, and bias 
−4.48%, 95% CIs of LoA -13.65 to 4.68, P 0.004, respectively; Fig. 5A). Strong agreement was observed between 
MEMRI T1 mapping (bias −0.14%, 95% CIs of LoA −5.72 to 5.43, P 0.70), as well as PET (bias −0.86%, 95% CIs 
of LoA −6.89 to 5.17, P = 0.58) and histological viability with MTC (Fig. 5Bi-ii). Similarly, with MEMRI T1 map-
ping and PET viability (bias 0.25%, 95% CIs of LoA −7.23 to 6.74, P = 0.86) although native T1 mapping tended 
to underestimate viable myocardium (bias −4.48%, 95% CIs of LoA −13.65 to 4.68, P = 0.004, Fig. 5Biii-iv).
Manganese and 18f-fDG uptake. On comparison of indexed T1 values with measures of 18F-FDG PET 
uptake, no correlation was evident between indexed native T1 mapping values and 18F-FDG PET SUV or Ki 
(r = −0.05, P = 0.87 and r < 0.01, P = 0.98). However, there was a negative correlation between MEMRI T1 map-
ping values and both 18F-FDG SUV and Ki (r = −0.66, P = 0.01 and r = −0.58, P = 0.04, Fig. 6).
Discussion
In this study, we have validated cardiac MEMRI quantification using both 18F-FDG and MTC as imaging and 
pathologic gold-standard assessments of myocardial viability respectively. In addition, MEMRI T1 values demon-
strated a relationship with 18F-FDG PET uptake suggesting both cellular calcium and glucose uptake are robust 
and concordant markers of myocardial viability. As a biologically active intracellular contrast agent, our study 
Figure 2. Viability quantification. Comparison of viability assessment by MEMRI, PET and MTC (n = 13). 
(MEMRI, manganese-enhanced magnetic resonance imaging; MTC, Masson’s trichrome; PET, positron 
emission tomography).
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clearly demonstrates that MEMRI holds major potential to characterise myocardial structure and function that is 
readily translatable into clinical practice.
Several preclinical studies have used MEMRI to show successful engraftment of stem cells in the myocar-
dium16,17. One clinical pilot study evaluated MEMRI in 10 patients following myocardial infarction, observ-
ing that regions remote to the infarct with preserved wall thickness were associated with increased manganese 
uptake18. However, this study did not use any other assessments of myocardial viability with which to compare 
the change in T1 signal. In the present study, we quantified viable myocardium with MEMRI T1 mapping which 
consistently demonstrated strong agreement with viability assessed by 18F-FDG PET, both of which were consist-
ent with histopathological definition of viability. 18F-FDG PET defines viable myocardium by identifying myo-
cardium with intact perfusion and preserved metabolism. We propose that MEMRI offers an MRI equivalent to 
this: an intracellular marker of viability that represents functional calcium-handling of contracting myocytes.
The question of what role non-invasive assessment of myocardial viability has in guiding revascularization 
therapies remains controversial and clinical trial data have yet to define its function in patient care. A substudy 
of the STICH trial19 looked for an association between myocardial viability quantification and clinical outcomes 
in patients undergoing revascularization or optimal medical therapy. Whilst observing no survival benefit in 
those with positive viability tests after adjustment for baseline variables, there were notable methodological 
shortcomings. Less than half of patients enrolled to this non-randomised substudy underwent viability testing 
and neither 18F-FDG PET or cardiac MRI were available at the time of enrolment. Furthermore, the viability 
assessments were dichotomised to presence or absence of viability only, without additional consideration of other 
important parameters of cardiac function. As such, the results of the study remain controversial. The AIMI-HF20 
aims to provide definitive answers to the question of viability in ischaemic cardiomyopathy, and there remains a 
good rationale that non-invasive myocardial viability assessment may benefit certain well-defined patient groups 
in accurate prognostication and targeted therapy. Indeed, in a sub-group analysis of the PARR-2 trial21 where 
patients undergoing 18F-FDG PET-directed therapy derived significant benefit.
In clinical practice, characterizing myocardial scar by DEMRI is perhaps the most available non-invasive 
assessment of myocardial viability, with a transmural extent of infarct threshold of ≤50% denoting a >40% 
chance of improved contractility following revascularization, irrespective of degree of wall motion defect2. This 
technique has been well-validated and is considered a reference standard22. However, despite its high spatial res-
olution, assessing the extent of transmural viability is highly dependent on ability to comply with breath-holding, 
which can be challenging in complex co-morbid cardiac patients. Presence of myocardial oedema in conjunc-
tion with the timing of imaging is also crucial to avoid overestimation of infarct size which is recognised with 
DEMRI23. Moreover, predicting the probability of contractile recovery following revascularization depends on a 
close relationship of myocardial scar volume to viability, which may be an inferior surrogate to a direct measure 
of viable myocardial volume such as with 18F-FDG PET, to which MEMRI is mechanistically a paramagnetic 
equivalent.
Whilst nephrogenic systemic fibrosis has been virtually eliminated in modern day MRI, further safety con-
cerns about gadolinium-based contrast media have arisen in recent years, predominantly over the discovery of 
gadolinium deposition in the basal ganglia with repeated exposure to linear chelates over time3–5. Although no 
definite pathological clinical sequelae have been identified to date, this has highlighted the current dependence 
Figure 3. Representative 18F-FDG PET, T1 mapping and histopathology. End-diastolic cine image of left 
ventricular short axis slice (A) with co-registered 18F-FDG PET (B), MTC (C) and MEMRI T1 mapping (D). 
Anterior myocardial infarction is evident by the absence of 18F-FDG PET uptake in the anterior wall. Percentage 
of viable myocardium for 18F-FDG PET, MEMRI T1 mapping and MTC are calculated as 80.56%, 80.60% and 
83.55% respectively. (18F-FDG, 18F fluorodeoxyglucose; MEMRI, manganese-enhanced magnetic resonance 
imaging; MTC, Masson’s trichrome; PET, positron emission tomography).
6Scientific RepoRtS |         (2020) 10:2018  | https://doi.org/10.1038/s41598-020-58716-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
on gadolinium-based contrast media and the increasingly urgent need for alternatives for paramagnetic or super-
paramagnetic magnetic resonance contrast imaging.
Of interest, the effect of manganese on T1 relaxivity correlated with both measures of 18F-FDG uptake. This 
indicates a key interrelationship between manganese and glucose uptake in viable cardiomyocytes, in remote as 
well as remodelling myocardium. Whilst it is not surprising that native T1 values showed no relationship with 
18F-FDG PET, MEMRI T1 values demonstrated a significant correlation with both measures of radiotracer uptake. 
For remote viable myocardium with greater 18F-FDG uptake to exhibit an association with greater manganese 
uptake, as evidenced by lower MEMRI T1 values in these matched regions, supports the hypothesis that track-
ing functional calcium-handling is a relevant marker of myocardial viability. Successful clinical translation of 
this novel myocardial imaging modality offers exciting potential for MEMRI to non-invasively quantify viability 
without the use of ionising radiation. Clinical trial of MEMRI of the myocardium is ongoing at the time of writ-
ing, demonstrating feasibility of this modality in application to ischaemic and non-ischaemic cardiomyopathy 
(NCT03607669). If successful, detection of altered calcium-handling with MEMRI has potential utility in ischae-
mic as well as non-ischaemic myocardial insults such as dilated cardiomyopathy, tako-tsubo cardiomyopathy and 
hypertrophic cardiomyopathy.
It is important to acknowledge some limitations to our study. First, as the experimental protocol was designed 
to compare two intracellular viability agents, direct comparison of these data with gadolinium DEMRI tech-
niques was not possible. However, the present study builds directly on our previous work which directly makes 
this comparison using an identical model and repetition of DEMRI was not considered ethically or scientifically 
Figure 4. Comparisons with histopathology. Bland-Altman plots comparing viability by native T1 mapping (A, 
P = 0.03), MEMRI T1 mapping (B, P > 0.9) and 18F-FDG PET (C, P > 0.9) against histopathological comparator 
(MTC, all n = 13). (CI, confidence intervals; 18F-FDG, 18F fluorodeoxyglucose; LOA, limits of agreement; 
MEMRI, manganese-enhanced magnetic resonance imaging; MTC, Masson’s trichrome; PET, positron 
emission tomography).
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justified11. Second, the use of a permanent coronary artery ligation model imaged at 12 weeks, may not reflect 
clinical disease as accurately as a reperfusion model, and longitudinal analysis limits the scope of our study. 
However, as we have previously published11, this model was chosen to result in myocardial infarction with a 
degree of left ventricular remodelling, providing a stable injury pattern from which robust comparisons can be 
drawn. Despite some variation in infarct size, all animals were included in the final analysis irrespective of viable 
myocardial percentage as each animal acted as its own control, demonstrating the ability of MEMRI to quantify 
myocardial viability in both extensive and subtle injury patterns. Finally, several additional challenges inherent to 
preclinical in vivo imaging (prolonged free-breathing T1 mapping sequences, variable and high heart and respira-
tory rates) with the lack of clinically available motion correction algorithms and small overall myocardial volume 
may have resulted in greater variability in the data, requiring normalisation. These challenges are not anticipated 
in clinical translation.
Figure 5. Comparisons with 18F-FDG PET. (A) Bland-Altman plots comparing viability by native T1 mapping 
and MEMRI T1 mapping against 18F-FDG PET (n = 13). (B) Bland-Altman plots comparing MEMRI T1 
mapping (i) and 18F-FDG PET (ii) and histopathological comparator (MTC). Agreement between native T1 
mapping (iii) and MEMRI T1 mapping (iv) with 18F-FDG PET (all n = 13). (CI, confidence intervals; 18F-FDG, 
18F fluorodeoxyglucose; LOA, limits of agreement; MEMRI, manganese-enhanced magnetic resonance imaging; 
MTC, Masson’s trichrome; PET, positron emission tomography).
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conclusion
For the first time, the present study validates the direct quantification of myocardial viability by MEMRI against 
18F-FDG PET imaging. Whilst 18F-FDG PET is the clinical gold-standard, it is limited by radiation exposure and 
the lack of dynamic functional and structural assessment that is made possible by MRI. In contrast, MEMRI 
adds quantification of intracellular calcium-handling to the already comprehensive single-point assessment of 
cardiac MRI. This technique has major potential for clinical application in the assessment of myocardial viability 
in ischaemic cardiomyopathy as well as non-ischaemic cardiomyopathy and regenerative myocardial therapies. 
Clinical translation of myocardial MEMRI is an essential next step and studies should focus on further charac-
terisation of uptake in healthy volunteers before applying MEMRI in patients with myocardial infarction and 
viability in ischaemic cardiomyopathy. Thereafter, application in non-ischaemic cardiomyopathy and assessments 
of regenerative therapies will be of major interest.
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